Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Melanoma 5Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 2vandetanib 1trametinib 1tislelizumab 1spartalizumab 1ribociclib 1naporafenib 1motesanib diphosphate 1milademetan 1fludarabine phosphate 1Specimen Handling 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Interleukin-13 1IFL protocol 1Gemcitabine 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × naporafenib × Dermatologic × Clear all
NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Novartis

Phase 1 Terminated
241 enrolled
DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡